Abstract:MicroRNAs (miRNAs) have emerged as key post-transcriptional regulators of gene expression, involved in diverse physiological and pathological processes. An oncogenic or tumor-suppressive miRNA may have potential as a therapeutic target to control cancers. Gefitinib is a tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR). H460 and A549 cells with EGFR receptor-independent over-activation of protein kinase B (Akt) or extracellular signal-regulated kinases (ERK) are significantly resistant to gefitinib. The first aim of this study was to confirm a role for three miRNAs (let-7a, hsa-miR-126, and hsa-miR-145) in the inhibition of proliferation in non-small cell lung cancer (NSCLC) cells. A second aim was to evaluate three miRNAs for their abilities to overcome cellular resistance and enhance the gefitinib cytotoxicity. The expression of miRNAs was estimated by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). Cell proliferation was examined by sulforhodamine B assay and tumor xenografts were measured in SCID/beige mice. The activation of Akt and ERK was observed by Western blotting. Forced expression of individual miRNA suppressed the growth of two cell lines and xenografts. The effect varied among different miRNAs and cells. Restoration of hsa-miR-126 more obviously inhibited cell growth than did restoration of hsa-miR-145 in both cells, and the suppressive effect was more significant in H460 xenografts than in A549 xenografts. Western blotting revealed that the inhibition of cell proliferation resulted from the inhibition of the activation of Akt and ERK. Moreover, forced expression of miRNAs contributed to enhanced cytotoxicity induced by gefitinib in lung cancer cells; especially in hsa-miR-126, the highest value of half max inhibitory (IC50) was increased sixfold. These findings confirm that tumor-suppressive miRNAs can inhibit the growth of NSCLC cells and enhance the targeted agents cytotoxicity, suggesting novel potential approaches to an improvement in chemotherapy.

Antagomir-1290 Suppresses CD133+ Cells in Non-Small Cell Lung Cancer by Targeting Fyn-Related Src Family Tyrosine Kinase

MiR-128 Reverses the Gefitinib Resistance of the Lung Cancer Stem Cells by Inhibiting the C-Met/pi3k/akt Pathway.

MiR-129-5p Inhibits Non-Small Cell Lung Cancer Cell Stemness and Chemoresistance Through Targeting DLK1.

MiR-129 Weakens Proliferation of Non-Small Cell Lung Cancer Cells via Targeted Regulation of High-Mobility Group AT-Hook 2

Mir-129-5p Attenuates Cell Proliferation and Epithelial Mesenchymal Transition Via HMGB1 in Gastric Cancer

Mir-301a-5p/Scin Promotes Gastric Cancer Progression Via Regulating Stat3 And Nf-Kappa B Signaling

MiR-129-5p Induces Cell Cycle Arrest Through Modulating HOXC10/Cyclin D1 to Inhibit Gastric Cancer Progression.

MiR-129 Blocks Estrogen Induction of NOTCH Signaling Activity in Breast Cancer Stem-Like Cells.

MicroRNA-34a Inhibits the Proliferation and Promotes the Apoptosis of Non-Small Cell Lung Cancer H1299 Cell Line by Targeting TGFβR2

MicroRNA-92 Expression in CD133+ Melanoma Stem Cells Regulates Immunosuppression in the Tumor Microenvironment via Integrin-Dependent Activation of TGFβ

MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.

MicroRNAs Reduce Tumor Growth and Contribute to Enhance Cytotoxicity Induced by Gefitinib in Non-Small Cell Lung Cancer

Mir-4666-3p and Mir-329 Synergistically Suppress the Stemness of Colorectal Cancer Cells Via Targeting TGF-β/Smad Pathway

The Effect of Microrna-129 on the Migration and Invasion in NSCLC Cells and Its Mechanism.

MiR-940 Inhibits the Progression of NSCLC by Targeting FAM83F.

MiR-1294, Mediated by KLF4, Negatively Regulates Cell Proliferation and Apoptosis by Targeting MYH9 in Non-Small Cell Lung Cancer

MicroRNA-1304 Suppresses Human Non-Small Cell Lung Cancer Cell Growth in Vitro by Targeting Heme Oxygenase-1

Mir-133A Functions As a Tumor Suppressor and Directly Targets FSCN1 in Pancreatic Cancer.

Mir-199A-3p/5p Regulate Tumorgenesis Via Targeting Rheb in Non-Small Cell Lung Cancer

MiR-1254 Suppresses HO-1 Expression Through Seed Region-Dependent Silencing and Non-Seed Interaction with TFAP2A Transcript to Attenuate NSCLC Growth

MiR‐34b‐3p Represses Cell Proliferation, Cell Cycle Progression and Cell Apoptosis in Non‐small‐cell Lung Cancer (NSCLC) by Targeting CDK4